Tuesday, May 01, 2007
Finally, after much success in dogs and mice, the use of adenovirus delivery of genes (RPE65) to correct vision problems is becoming a reality in patients. And so far it looks good. I see this as a major step forward in the visionary method of gene therapy, with foresight. There are many advantages to this method of trans-retinal injection, since the eye is immune privileged, and easy to monitor by peering into it.